STUDIES OF PHOTOTHERAPY FOR THORACIC MALIGNANCIES

胸部恶性肿瘤光疗的研究

• 批准号: 3916630
• 负责人: H I PASS
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3916630
• 关键词: adenocarcinoma; cytotoxicity; disease /disorder model; fibroblasts; human subject; laboratory rat; light scattering; lung neoplasms; mesothelioma; metastasis; monoclonal antibody; neoplasm /cancer photoradiation therapy; neoplasm /cancer relapse /recurrence; ovary neoplasms; phototherapy; porphyrins; radioimmunoassay; tissue /cell culture; trachea neoplasm

Our laboratory has continued investigations of photodynamic therapy (PDT) for the treatment of thoracic malignancies by sensitization of malignant cells with dihematoporphyrin ether (DHE) followed by illumination with 630 nM light. Since October of 1987 we have investigated the use of light scattering media, intra-lipid, in different concentrations to improve the efficacy of PDT. We have found that low concentrations of intra-lipid will provide greater cytotoxicity via PDT, with greater light-scattering effects despite a loss of the sensitizer from the cells during the period of incubation with the intra-lipid. Using a phantom plexiglass model of the thoracic cavity, we have defined what the optimal light scattering concentration in this model is for intra-lipid in order to provide equal illumination to all surfaces. We have quantitated light scattering using a photodiode detection system, constructed by the Bioengineering Division. We are now investigating different in vitro PDT sensitivities of various thoracic, oncologic cell lines including a small-cell lung cancer variant, a large-cell carcinoma of the lung, mesothelioma, normal lung fibroblasts and an adenocarcinoma. For each of these cell lines we are defining fluourescence characteristics of the cells, cell size, cell protein, and inherent sensitivity to low energy phototherapy. The role of LDL receptors in the delivery of DHE at a cellular level is also being investigated. In preparation for conjugation of a monoclonal antibody to the sensitizor, in vitro and in vivo studies of PDT of a transformed fibroblast line, 45342 have been performed showing sensitivity of this line to PDT both in vitro and in vivo. We have now treated 9 patients with endobronchial disease with PDT and have made a movie demonstrating the technique of phototherapy. Two patients with recurrent ovarian carcinomatosis have been treated with intraabdominal PDT.

我们的实验室继续研究光动力疗法 (PDT)用于通过致敏治疗胸部恶性肿瘤 二血卟啉醚（DHE）的恶性细胞， 用630 nM光照射。 自1987年10月以来， 研究了脂质内光散射介质的使用， 不同的浓度，以提高PDT的疗效。 我们有 发现低浓度的内脂质将提供更大的 通过PDT的细胞毒性，具有更大的光散射效应，尽管 致敏剂在给药期间从细胞中损失， 与内脂质孵育。 使用一个幻影有机玻璃模型 我们已经定义了胸腔的最佳光线 该模型中的散射浓度是针对脂质内的， 以向所有表面提供相等的照明。 我们已经量化了 使用光电二极管检测系统的光散射， 由生物工程部 我们现在正在调查不同的 不同胸肿瘤细胞体外PDT敏感性 包括小细胞肺癌变异，大细胞肺癌变异， 肺癌、间皮瘤、正常肺成纤维细胞和 腺癌 对于这些细胞系中的每一个， 细胞的荧光特性，细胞大小，细胞 蛋白质和对低能量光疗的固有敏感性。 的 LDL受体在细胞水平DHE传递中的作用 也在调查中。 在准备缀合a 致敏剂的单克隆抗体，体外和体内研究 对转化的成纤维细胞系45342进行了PDT 显示了该细胞系在体外和体内对PDT的敏感性。 我们现在已经用PDT治疗了9例支气管内疾病 并制作了一部展示光疗技术的电影。 两名复发性卵巢癌患者， 腹腔内PDT治疗。